Finally, the MONALEESA-3 study was a phase III, randomised (2:1), placebo-controlled clinical trial which included postmenopausal patients with advanced breast cancer, positive hormone receptors, and HER-2 negative. This evidence concerns the gene ERBB2 and breast carcinoma.